Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BoneAlbumin is a serum albumin-coated bone allograft developed by OrthoSera GmbH for bone regeneration applications. It consists of demineralized bone matrix or freeze-dried bone allograft coated with human serum albumin, making it a human tissue product derived from donated bone and blood. The biological mechanism involves the albumin coating activating endogenous mesenchymal stem cells (MSCs) and progenitor cells, facilitating their attachment and proliferation on the bone surface. This process results in accelerated bone formation, increased mechanical strength, and improved tissue remodeling compared to standard uncoated bone grafts. BoneAlbumin is utilized in various orthopedic and dental procedures, including the treatment of critical size bone defects, sinus floor augmentation, and anterior cruciate ligament reconstruction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BoneAlbumin.